http://jcps.bjmu.edu.cn
Cost-effectiveness analysis of tyrosine kinase inhibitors (erlotinib, gefitinib, afatinib and osimertinib) as first-line therapy for epidermal growth factor receptor-mutated advanced non-small cell lung cancer
Shaohong Luo, Liangliang Dong, Yiyuan Li, Dan Xu, Min Chen
Journal of Chinese Pharmaceutical Sciences . 2021, (3): 253 -263 .  DOI: 10.5246/jcps.2021.03.021

About Journal | Info for Authors | Statements | Peer Review Policy | Submission | Copyright Info
京ICP备05051953号-7
Copyright © Journal of Chinese Pharmaceutical Sciences, School of Pharmaceutical Sciences, Peking University
Tel./Fax: +86-10-82801713, E-mail: jcps@bjmu.edu.cn
Powered by Beijing Magtech Co., Ltd.